Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.

Autor: Navarro-Ocón A; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain., Blaya-Cánovas JL; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.; UGC de Oncología Médica, Complejo Hospitalario de Jaen, 23007 Jaen, Spain., López-Tejada A; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.; Department of Biochemistry and Molecular Biology 2, School of Pharmacy, University of Granada, 18011 Granada, Spain., Blancas I; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.; UGC de Oncología, Hospital Universitario 'San Cecilio', 18016 Granada, Spain., Sánchez-Martín RM; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain., Garrido MJ; Department of Pharmaceutical Technology and Chemistry, School of Pharmacy & Nutrition, Navarra Institute for Health Research (IdisNA), University of Navarra, 31080 Pamplona, Spain., Griñán-Lisón C; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.; UGC de Oncología Médica, Complejo Hospitalario de Jaen, 23007 Jaen, Spain., Calahorra J; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.; UGC de Oncología Médica, Complejo Hospitalario de Jaen, 23007 Jaen, Spain., Cara FE; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain., Ruiz-Cabello F; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.; Department of Biochemistry, Molecular Biology 3 and Immunology, School of Medicine, University of Granada, 18071 Granada, Spain., Marchal JA; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.; Department of Human Anatomy and Embryology, School of Medicine, University of Granada, 18016 Granada, Spain., Aptsiauri N; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.; Department of Biochemistry, Molecular Biology 3 and Immunology, School of Medicine, University of Granada, 18071 Granada, Spain., Granados-Principal S; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, 18016 Granada, Spain.; Instituto de Investigación Biosanitaria (ibs.GRANADA), 18012 Granada, Spain.; Department of Biochemistry and Molecular Biology 2, School of Pharmacy, University of Granada, 18011 Granada, Spain.
Jazyk: angličtina
Zdroj: Pharmaceutics [Pharmaceutics] 2022 Feb 25; Vol. 14 (3). Date of Electronic Publication: 2022 Feb 25.
DOI: 10.3390/pharmaceutics14030505
Abstrakt: Breast cancer is the most common type of malignancy and leading cause of cancer death among women worldwide. Despite the current revolutionary advances in the field of cancer immunotherapy, clinical response in breast cancer is frequently below expectations, in part due to various mechanisms of cancer immune escape that produce tumor variants that are resistant to treatment. Thus, a further understanding of the molecular events underlying immune evasion in breast cancer may guarantee a significant improvement in the clinical success of immunotherapy. Furthermore, nanomedicine provides a promising opportunity to enhance the efficacy of cancer immunotherapy by improving the delivery, retention and release of immunostimulatory agents in targeted cells and tumor tissues. Hence, it can be used to overcome tumor immune escape and increase tumor rejection in numerous malignancies, including breast cancer. In this review, we summarize the current status and emerging trends in nanomedicine-based strategies targeting cancer immune evasion and modulating the immunosuppressive tumor microenvironment, including the inhibition of immunosuppressive cells in the tumor area, the activation of dendritic cells and the stimulation of the specific antitumor T-cell response.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje